Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2014 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Amortization of Deferred Charges of $681000.0 for Q1 2026, up 69.83% year-over-year from $401000.0 in Q1 2025, and up 37.58% quarter-over-quarter from $495000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 13 years of Amortization of Deferred Charges data on file, last reported at $681000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $681000.0, up 69.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 14.52% YoY), and the FY2025 annual result was $1.7 million, down 7.86% from the prior year.
- Amortization of Deferred Charges rose to $681000.0 in Q1 2026 per LXRX's latest filing, from $495000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $681000.0 in Q1 2026 and troughed at $25000.0 in Q1 2022.
- A 5-year average of $396529.4 and a median of $402000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges surged 4212.5% in 2022, then plunged 35.11% in 2024.
- A 5-year view of Amortization of Deferred Charges shows it stood at $345000.0 in 2022, then jumped by 79.13% to $618000.0 in 2023, then sank by 35.11% to $401000.0 in 2024, then advanced by 23.44% to $495000.0 in 2025, then jumped by 37.58% to $681000.0 in 2026.
- Business Quant data shows LXRX's Amortization of Deferred Charges at $681000.0 in Q1 2026, $495000.0 in Q4 2025, and $402000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 681,000.00 |
| Mar 31, 2026 | 681,000.00 |
| Dec 31, 2025 | 495,000.00 |
| Dec 31, 2025 | 495,000.00 |
| Sep 30, 2025 | 402,000.00 |
| Sep 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | 401,000.00 |
| Mar 31, 2025 | 401,000.00 |
| Dec 31, 2024 | 401,000.00 |
| Dec 31, 2024 | 401,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 525,000.00 |
| Jun 30, 2024 | 525,000.00 |
| Mar 31, 2024 | 517,000.00 |
| Mar 31, 2024 | 517,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Dec 31, 2023 | 618,000.00 |